Temaccord New Zealand - English - Medsafe (Medicines Safety Authority)

temaccord

douglas pharmaceuticals limited - temozolomide 180mg;   - capsule - 180 mg - active: temozolomide 180mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

Temaccord New Zealand - English - Medsafe (Medicines Safety Authority)

temaccord

douglas pharmaceuticals limited - temozolomide 20mg;   - capsule - 20 mg - active: temozolomide 20mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

Temaccord New Zealand - English - Medsafe (Medicines Safety Authority)

temaccord

douglas pharmaceuticals limited - temozolomide 250mg;   - capsule - 250 mg - active: temozolomide 250mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

Temaccord New Zealand - English - Medsafe (Medicines Safety Authority)

temaccord

douglas pharmaceuticals limited - temozolomide 5mg;   - capsule - 5 mg - active: temozolomide 5mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

TEMACCORD Australia - English - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; colloidal anhydrous silica; sodium starch glycollate; tartaric acid; stearic acid; lactose; purified water; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - English - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: purified water; lactose; titanium dioxide; colloidal anhydrous silica; iron oxide yellow; gelatin; tartaric acid; stearic acid; sodium starch glycollate; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - English - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: gelatin; purified water; indigo carmine; colloidal anhydrous silica; stearic acid; titanium dioxide; tartaric acid; sodium starch glycollate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - English - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: titanium dioxide; colloidal anhydrous silica; stearic acid; gelatin; tartaric acid; iron oxide red; purified water; sodium starch glycollate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - English - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 20 mg - capsule, hard - excipient ingredients: titanium dioxide; colloidal anhydrous silica; sodium starch glycollate; lactose; iron oxide yellow; gelatin; tartaric acid; purified water; stearic acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - English - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 5 mg - capsule, hard - excipient ingredients: titanium dioxide; iron oxide yellow; sodium starch glycollate; lactose; tartaric acid; purified water; stearic acid; gelatin; colloidal anhydrous silica; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.